Advenchen 
Welcome,         Profile    Billing    Logout  
 5 Products   33 Diseases   5 Products   1369 Trials   5508 News 


«12...1819202122232425262728...4748»
  • ||||||||||  exlinkibart (LVGN6051) / Lyvgen
    Enrollment open, IO biomarker, Metastases:  A Study of LVGN6051 Combined with Anlotinib in Patient with Soft Tissue Sarcoma (clinicaltrials.gov) -  Jun 1, 2022   
    P1/2,  N=65, Recruiting, 
    However, the tumor did not respond to apatinib and anlotinib treatment, and the patient died 10 months after the initial diagnosis. Not yet recruiting --> Recruiting
  • ||||||||||  Kaitanni (cadonilimab) / Akesobio
    Enrollment closed:  A Trial of AK104 Plus Anlotinib in NSCLC (clinicaltrials.gov) -  May 25, 2022   
    P1/2,  N=114, Active, not recruiting, 
    This conclusion should be validated in prospective clinical trials. Recruiting --> Active, not recruiting
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    Journal:  Anlotinib in recurrent or metastatic endometrial cancer. (Pubmed Central) -  May 24, 2022   
    Anlotinib is effective and well tolerated in patients with recurrent or metastatic endometrial cancer. It may be considered a choice for patients younger than 60 years and who have had <3 lines of treatment.
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    Retrospective data, Review, Journal, Real-world evidence:  Retrospective Review of Efficacy and Safety of Anlotinib in Advanced Leiomyosarcoma: A Real-World Study. (Pubmed Central) -  May 20, 2022   
    Our results forecast that anlotinib is effective, safe and alternative in treatment of advanced leiomyosarcoma in real-world, combined with immunotherapy may become a potential treatment option. Further, more prospective randomized controlled trials are needed to confirm these findings.
  • ||||||||||  Opdivo (nivolumab) / BMS, Focus V (anlotinib) / Advenchen, Sino Biopharm
    Trial completion date, Trial primary completion date, Combination therapy:  Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors (clinicaltrials.gov) -  May 6, 2022   
    P1/2,  N=56, Recruiting, 
    Collectively, ADAR1 deficiency increased the sensitivity of NSCLC/AR cells to anlotinib by downregulating CX3CL1, which might provide a potential strategy for NSCLC/AR therapy. Trial completion date: Dec 2022 --> Mar 2023 | Trial primary completion date: Dec 2021 --> Dec 2022
  • ||||||||||  Halaven (eribulin mesylate) / Eisai, Focus V (anlotinib) / Advenchen, Sino Biopharm
    Trial completion date, Metastases:  Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast Cancer (clinicaltrials.gov) -  May 6, 2022   
    P2,  N=64, Recruiting, 
    This study indicates that anti-PD-1 antibody combined with anlotinib and pegaspargase is a promising chemoradiotherapy regimen for localized NTKL, with mild toxicity and good tolerance. Trial completion date: Aug 2022 --> May 2022
  • ||||||||||  docetaxel / Generic mfg., gemcitabine / Generic mfg.
    Trial completion date, Trial primary completion date:  PROACH: Pulmonary Resectable Metastases of Osteosarcoma With Anti-angiogenics and CHemotherapy (clinicaltrials.gov) -  May 5, 2022   
    P2,  N=43, Recruiting, 
    The conclusion should be validated in prospective clinical trials subsequently. Trial completion date: Sep 2022 --> Dec 2023 | Trial primary completion date: Apr 2022 --> Jul 2023
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    Biomarker, Trial completion date, Trial primary completion date, Metastases:  BIOVAS: BIOmarker Driven Trial of VEGFR2 Inhibitor in Advanced Sarcoma (clinicaltrials.gov) -  Apr 29, 2022   
    P2,  N=30, Recruiting, 
    The combination of anlotinib and PD-1 monoclonal antibody is beneficial to GC therapy. Trial completion date: May 2022 --> Aug 2023 | Trial primary completion date: Dec 2021 --> Feb 2023
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    A nomogram to predict the prognosis of advanced soft tissue sarcoma patients treated with anlotinib: A real-world population-based study. () -  Apr 28, 2022 - Abstract #ASCO2022ASCO_6355;    
    Anlotinib has shown encouraging anti-tumor activity and well tolerance in the first-line treatment of locally advanced or metastatic soft-tissue sarcoma who were not suitable for chemotherapy. The nomogram based on ECOG performance status, FNCLCC grade, nutritional status, neutrophil count, and treatment patterns can accurately predict the 1-year and 2-year OS probability for advanced STS patients treated with anlotinib.
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm, APL-502 / Apollomics
    Phase Ib study of anlotinib in combination with anti-PD-L1 ab (TQB2450) in patients with advanced acral melanoma. () -  Apr 28, 2022 - Abstract #ASCO2022ASCO_6329;    
    P1/2
    The nomogram based on ECOG performance status, FNCLCC grade, nutritional status, neutrophil count, and treatment patterns can accurately predict the 1-year and 2-year OS probability for advanced STS patients treated with anlotinib. The combination of TQB2450 plus anlotinib showed promising benefit and was tolerable in patients with advanced acral melanoma, which needed further investigation of the combination therapy in advanced acral melanoma.
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    A phase I study of anlotinib with concurrent chemoradiotherapy for limited-stage small cell lung cancer. (Available On Demand; 205) -  Apr 28, 2022 - Abstract #ASCO2022ASCO_5652;    
    P1
    Patients received anlotinib (12mg, qd, d1-14, q3w) and chemotherapy (etoposide, 100 mg/m2, d1-3, q3w and cisplatin, 25 mg/m2, d1-3, q3w) for cycle 1, then anlotinib [dose escalation at 3 levels (DL1-3) 8mg, 10mg and 12mg, qd, d1-14, q3w], chemotherapy (etoposide, 50 mg/m2, d1-5, q4w and cisplatin, 25 mg/m2, d1-3, q4w) and thoracic radiotherapy (60-66 Gy in 30-33 daily 2-Gy fractions starting on day 1 of cycle 2) for cycles 2–3, then anlotinib (12mg, qd, d1-14, q3w) and chemotherapy (etoposide, 100 mg/m2, d1-3, q3w and cisplatin, 25 mg/m2, d1-3, q3w) for cycles 4-6. Combined treatment with anlotinib and CCRT for limited-stage small cell lung cancer is well tolerated and further clinical investigation is warranted.